Sanofi Pasteur and Syntiron to develop MRSA vaccine
Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, has signed an exclusive, worldwide licensing agreement with Syntiron to develop and commercialise its prophylactic vaccine against Staphylococcus, including Staphylococcus aureus or MRSA.
Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, has signed an exclusive, worldwide licensing agreement with Syntiron to develop and commercialise its prophylactic vaccine against Staphylococcus, including Staphylococcus aureus or MRSA.
Syntiron is a private biotech company located in St. Paul, Minnesota, US.
Under the terms of the agreement, Sanofi Pasteur will support the joint, pre-clinical development of the vaccine and take responsibility for all future developments, regulatory approval, and commercialisation.
The agreement includes an undisclosed initial licensing fee, milestone payments and royalties on future sales.
"Along with our development of a vaccine to prevent Clostridium difficile infection (CDI), the successful development of a vaccine to prevent MRSA would be a major achievement in combating hospital-associated infections," said Wayne Pisano, chief executive of Sanofi Pasteur.